The first clinical trials of Mediator kinase inhibitors have been conducted in estrogen receptor–positive breast cancers (ClinicalTrials.gov Identifier: NCT03065010) and should be initiated soon in acute myeloid leukemia (AML). The gene discussed is ESR1; the disease is breast carcinoma.